Generics win anti-pay-for-delay bill challenge

The Association for Accessible Medicines (AAM), which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

FTC insists generics ANI and Novitium divest IP before merger

11 November 2021 The Federal Trade Commission has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger.

Generics

Teva sues two Indian generics over Huntington’s treatment

6 July 2021 Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.

Americas

Judge partially revives California pay-for-delay ban

17 February 2022 A Californian judge has partially revived the state’s pay-for-delay ban after attorney general Rob Bonta requested that a preliminary injunction against the ban be modified.

More on this story

article

FTC insists generics ANI and Novitium divest IP before merger

11 November 2021 The Federal Trade Commission has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger.

Generics

Teva sues two Indian generics over Huntington’s treatment

6 July 2021 Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.

Americas

Judge partially revives California pay-for-delay ban

17 February 2022 A Californian judge has partially revived the state’s pay-for-delay ban after attorney general Rob Bonta requested that a preliminary injunction against the ban be modified.

More on this story

article

FTC insists generics ANI and Novitium divest IP before merger

11 November 2021 The Federal Trade Commission has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger.

Generics

Teva sues two Indian generics over Huntington’s treatment

6 July 2021 Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.

Americas

Judge partially revives California pay-for-delay ban

17 February 2022 A Californian judge has partially revived the state’s pay-for-delay ban after attorney general Rob Bonta requested that a preliminary injunction against the ban be modified.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

Generics win anti-pay-for-delay bill challenge

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features